Meeting
2021 ASCO Annual Meeting
Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.
Authors
Viola Weijia Zhu
Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA
Viola Weijia Zhu , Christine M. Bestvina , Gilberto Lopes , John Turner Hamm , Melissa Lynne Johnson , Philip Edward Lammers , Xiuning Le , Omkar Marathe , Luis E. Raez , Suman Rao , Joshua K. Sabari , Ronald J. Scheff , Umit Tapan , Jonathan Robert Thompson , Niki Karachaliou , Barbara Ellers-Lenz , Sabine Brutlach , Egbert F. Smit , Yi-Long Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03940703
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS9136)
DOI
10.1200/JCO.2021.39.15_suppl.TPS9136
Abstract #
TPS9136
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Stepwise prolongation of overall survival from first- to third-generation EGFR-tyrosine kinase inhibitors in non-small cell lung cancer and the prognostic impact of concomitant antacids.
First Author: Kiyoaki Uryu
Poster
2023 ASCO Annual Meeting
Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib.
First Author: Daniel Shao-Weng Tan
Poster
2017 ASCO Annual Meeting
Phase Ib study of tepotinib in EGFR-mutant/c-Met-positive NSCLC: Final data and long-term responders.
First Author: Yi-Long Wu
Poster
2024 ASCO Annual Meeting
A multicenter, prospective phase II trial of first-line osimertinib treatment for patients with poor performance status and EGFR mutation–positive non-small cell lung cancer (OPEN/TORG2040).
First Author: Nobuaki Mamesaya